Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven + HMA treatment outcome among 32 patients (median age...

Descripción completa

Detalles Bibliográficos
Autores principales: Gangat, Naseema, Guglielmelli, Paola, Szuber, Natasha, Begna, Kebede H., Patnaik, Mrinal M., Litzow, Mark R., Al‐Kali, Aref, Foran, James M., Palmer, Jeanne M., Alkhateeb, Hassan, Elliott, Michelle A., Hanson, Curtis A., Pardanani, Animesh, Mannelli, Francesco, Vannucchi, Alessandro M., Tefferi, Ayalew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251544/
https://www.ncbi.nlm.nih.gov/pubmed/33844862
http://dx.doi.org/10.1002/ajh.26186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251544/
https://www.ncbi.nlm.nih.gov/pubmed/33844862
http://dx.doi.org/10.1002/ajh.26186

Ejemplares similares